how to use a reference scaled average bioequivalence approach for narrow therapeutic index drugs
Published 5 years ago • 2.2K plays • Length 36:57Download video MP4
Download video MP3
Similar videos
-
58:30
how to demonstrate virtual bioequivalence for complex dermal generic drugs
-
20:11
topical dosage forms: emerging insights and implications for bioequivalence approaches
-
59:49
pbpk modeling approaches to assess risks associated with bioequivalence in drug development
-
49:08
achieving virtual bioequivalence with pbpk in lieu of clinical studies
-
1:07:07
submerge in the oligonucleotide emerge: best practices for developing these complex biologics
-
25:00
oligonucleotide therapeutic development: pre-clinical and translational considerations
-
7:33
certara: biosimulation paves the way for precision dosing
-
43:45
found in translation building an early development strategy for complex biologics
-
49:10
improve your success rate in costly bioequivalence studies with ivivc
-
44:35
developing robust potency assays for validation - a case study
-
57:06
small molecules, biologics, and vaccines: three uniquely divergent roads to fda cmc approval
-
44:54
how model based personalized drug dosing will revolutionize healthcare
-
57:02
how to optimize your drug label using biosimulation methodology
-
39:55
from research to translational medicine
-
5:33
landscape of oa drug and biologic development, cder regulatory perspective | robert shibuya
-
31:25
janne lehtio - data driven precision medicine and diagnostics - keynote
-
1:47
the value of basecase
-
33:15
efficient categorization leads to efficient analysis
-
30:48
breakout 1.5 - eatris (european infrastructure for translational medicine)
-
1:00
your first choice in complex biologics drug development
-
1:07
if your drug is a cyp3a substrate, we have good news for you!
-
6:46
the biomarker qualification process: a roadmap for requestors